A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting now

Conditions studied: Follicular Lymphoma

In brief

This study aims to observe and explore the efficacy and safety of obinutuzumab-based therapy for previously untreated follicular lymphoma

Key facts

Study ID

NCT05899621

Run by

Ruijin Hospital

People needed

332

Starts

2023-06-01

Expected to finish

2027-06-30

Last updated by the study team

2023-06-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathologically confirmed CD20 positive follicular lymphoma grade 1, 2, or 3A based on 2016 WHO classification
• Treatment naive
• Age ≥ 18 years
• Indications for treatment confirmed
• Must has measurable lesion in CT or PET-CT prior to treatment
• Considered suitable for GR, GB or GCHOP regimens
• Informed consented

You may not qualify if…

• Transformed follicular lymphoma or 3B follicular lymphoma;
• HBsAg positive and / or HBcAb positive with HBV DNA titer; HCV antibody positive with HCV-RNA; or HIV positive
• Central nervous system or meninges involved
• Any drug contraindication in the treatment plan
• Patients judged by other researchers to be unsuitable for inclusion in the study

Where it is running

• Ruijin Hospital, Shanghai Jiao Tong University School of Medicine — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.